Get the Stockscreener App
2.83
8.71%
-0.27
BioAtla Inc stock is currently priced at $2.83, with a 24-hour trading volume of 570.64K.
It has seen a -8.71% decreased in the last 24 hours and a +11.86% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.11 pivot point. If it approaches the $2.71 support level, significant changes may occur.
Previous Close:
$3.10
Open:
$3.12
24h Volume:
570.64K
Market Cap:
$136.17M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-1.0888
EPS:
-2.5993
Net Cash Flow:
$-104.11M
1W Performance:
+4.43%
1M Performance:
+11.86%
6M Performance:
+73.62%
1Y Performance:
-19.37%
1D Range:
$2.82
$3.16
52W Range:
$1.24
$4.02
BioAtla Inc Stock (BCAB) Company Profile
Name
BioAtla Inc
Sector
Industry
Phone
858 558 0708
Address
11085 Torreyana Road, San Diego
BioAtla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
BioAtla Inc Stock (BCAB) Latest News
Q2 2024 Earnings Forecast for BioAtla, Inc. Issued By HC Wainwright (NASDAQ:BCAB) - Defense World
Defense World
Q2 2024 EPS Estimates for BioAtla, Inc. Raised by HC Wainwright (NASDAQ:BCAB) - MarketBeat
MarketBeat
BioAtla Inc [BCAB] Records 200-Day SMA of $2.31 – Knox Daily - Knox Daily
Knox Daily
BioAtla (NASDAQ:BCAB) Rating Reiterated by HC Wainwright - Defense World
Defense World
Simplex Trading LLC Cuts Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
Defense World
BioAtla Inc (BCAB) Stock: A Year of Highs and Lows - The InvestChronicle
The InvestChronicle
BioAtla Inc Stock (BCAB) Financials Data
BioAtla Inc (BCAB) Net Income 2024
BCAB net income (TTM) was -$123.46 million for the quarter ending December 31, 2023, a -15.95% decrease year-over-year.
BioAtla Inc (BCAB) Cash Flow 2024
BCAB recorded a free cash flow (TTM) of -$104.11 million for the quarter ending December 31, 2023, a -14.80% decrease year-over-year.
BioAtla Inc (BCAB) Earnings per Share 2024
BCAB earnings per share (TTM) was -$2.59 for the quarter ending December 31, 2023, a +3.69% growth year-over-year.
BioAtla Inc Stock (BCAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SHORT JAY M PHD | Chief Executive Officer |
Dec 20 '23 |
Buy |
2.14 |
50,000 |
106,910 |
1,439,283 |
| STEINMAN LAWRENCE | Director |
Dec 19 '23 |
Buy |
2.05 |
20,000 |
41,048 |
38,459 |
| Vasquez Christian | See Remarks |
Dec 19 '23 |
Buy |
2.04 |
7,495 |
15,262 |
115,659 |
| MCBRINN SYLVIA | Director |
Sep 08 '23 |
Buy |
2.54 |
2,000 |
5,080 |
11,125 |
About BioAtla Inc
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
0.77%
1.20%
Cap:
|
Volume (24h):